Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Jun 30, 2021
    - New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)
    - The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe
    - XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants
  • Jun 28, 2021
    - Panbio™ COVID-19 Antigen Self-Test is approved for sale directly to consumers and for use in adults and children with or without symptoms, enabling fast, convenient coronavirus testing
    - The self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - In clinical evaluations with self-test users, the Panbio Self-Test correctly identified 95.2% of positive samples and 100% of negative samples
    - Abbott is the only diagnostics manufacturer to provide performance data on a rapid antigen test specific for use on children who are 15 years and younger, including infants
    - Together with vaccines and health protocols, frequent, regular screening of asymptomatic and symptomatic people can restore a sense of safety and stability as more people return to work, school, family gatherings and recreational activities
  • Jun 25, 2021
    - Comparative data presented at the American Diabetes Association 81st Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population
    - Priced at a third of the cost of other available continuous glucose monitoring systems(3), data suggests increasing use of FreeStyle Libre system could save Medicaid millions annually(4) by reducing costly complications
    - The groundbreaking FreeStyle Libre portfolio has been extensively studied with real-world data from more than 1 million users(5) and clinical evidence, showing it helps people with diabetes significantly improve their health and quality of life(6)
  • Jun 24, 2021
    - Survey reveals nearly half of people who report regular, intense exercise believe that energy drinks and soda can aid in rehydration after exercising; however, these beverages do not meet scientific experts' recommendations for rehydration¹,²,³
    - Abbott, maker of Pedialyte®, teams up with fitness coach Jeanette Jenkins to encourage smart hydration
  • Jun 7, 2021
    - First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation
    - New delivery system works with Abbott's leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and seals off a broad range of LAA anatomies
    - Steerable sheath gives physicians enhanced flexibility and precise placement when implanting Amplatzer Amulet
  • Jun 7, 2021
    - All 16 Walgreens locations in the city of Philadelphia will provide the rapid BinaxNOW™ COVID-19 Antigen Self Test at no cost to customers who present a Pennsylvania EBT ACCESS Card, starting June 7 and running through July 4
    - First-of-its-kind pilot program aims to increase consumer access to rapid testing
    - BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and has been available nationwide for over-the-counter (OTC), non-prescription purchase at Walgreens since mid-April
  • Jun 3, 2021
    - Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD)
    - Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life
    - Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) alongside training and education for implanting physicians now offering Abbott's HeartMate 3™ to their patients
  • May 17, 2021
    - Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant
    - The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
  • May 12, 2021
    - Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria
    - United customers can depart the U.S. with the Abbott BinaxNOW™ Home Test in their carry-on bag and administer the test via the eMed digital health platform to re-enter the U.S.
  • May 6, 2021
    - A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure
    - The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats
    - Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
  • Apr 26, 2021
    - New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)
    - Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment
    - Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
  • Apr 19, 2021
    - BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription
    - Abbott to manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand
    - The BinaxNOW Self Test will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S.
  • Apr 12, 2021
    - Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons
    - Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games
    - Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance
  • Apr 8, 2021
    - New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
    - Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy
    - TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
  • Apr 6, 2021
    - New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding
    - XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT
    - Recent data demonstrate XIENCE with short DAPT does not increase cardiac events and reduces severe bleeding, further confirming the leading safety profile of the XIENCE stent
  • Mar 31, 2021
    - FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms
    - The BinaxNOW COVID-19 Self Test is identical to the professional-use test, used since August 2020, bringing the most studied and widely used rapid antigen test to retail shelves across the country
    - BinaxNOW Self Test will be available nationwide and in large quantities at major food, drug and mass merchandiser retailers nationally and will be priced affordably, similar to common over-the-counter (OTC) tests
    - Together with vaccines, serial testing of asymptomatic people will help restore a sense of safety in everyday settings where people gather
    - Asymptomatic multi-test authorization also applies to BinaxNOW professional-use test
  • Mar 8, 2021
    - Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location*
    - NeuroSphere Virtual Clinic utilizes advancements made in digital technology to optimize care through intuitive tools that enhance therapy management
    - Virtual clinic technology can change the treatment approach for patients who live far from necessary medical care or who are burdened by visiting the doctor in person
  • Mar 5, 2021
    -- Abbott's Alinity™ m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms
    -- The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab
    -- Assay will run on Abbott's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes
    -- Abbott also received updated EUA for asymptomatic usage of its Alinity m SARS-CoV-2 assay
  • Jan 26, 2021
    - Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
    - Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
    - Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision
    - Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
    - Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
    - Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
  • Jan 20, 2021
    - New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
  • Jan 14, 2021
    - New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data
    - NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system
  • Jan 12, 2021
    - Abbott will complete the U.S. government order for 150 million BinaxNOW COVID-19 tests this week and will supply 30 million additional tests through March via a new government order
    - Company is in final stages of completing its self-funded capacity expansion across U.S. manufacturing sites
    - Abbott has the most advanced and comprehensive COVID-19 rapid test portfolio available today, including ID NOW, BinaxNOW, the BinaxNOW at-home test and the NAVICA app
    - Workplaces, universities, schools and other qualified organizations that need frequent and affordable testing can now directly procure BinaxNOW tests from Abbott
  • Jan 11, 2021
    - The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT™ Alinity™ handheld device
    - Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%
    - The test simultaneously measures biomarkers UCH-L1 and GFAP, proteins found in the blood after a concussion or head trauma
    - Building on this initial clearance, Abbott is also working on a test that would use whole blood on i-STAT at the point of care, and developing a test for its Alinity™ i and ARCHITECT® core laboratory instruments under FDA breakthrough designation
  • Dec 17, 2020
    - Abbott's HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure
    - This life-saving technology provides new treatment option for underserved population
  • Dec 16, 2020
    - First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes
    - Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter
    - $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process
    - BinaxNOW is a highly portable, easy-to-use, 15-minute antigen test with no instrument that detects the virus when people are most infectious, which is critically important in slowing the spread of the virus
    - Service uses Abbott's complementary NAVICA™ app to enable the testing process and display authenticated BinaxNOW test results verified by a trained guide - and supports consumer confidence in testing at home
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?